ong-term safety of TP-03 treatment for Demodex blepharitis

Not Applicable

• Conditions: Blepharitis due to Demodex infestation; Eye Diseases; Blepharitis

• Registration Number: ISRCTN49009434
• Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-09
• Last Update Posted: 22 March 2021
• Study Completion: 2022-02-28

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 418

Inclusion Criteria

1. Male or female, aged =18 years of age
2. Participants must have been treated with TP-03 or the vehicle of TP-03 for 43 days
3. Be willing to sign IRB-approved informed consent and deemed capable of complying with the requirements of the study protocol
4. Be willing to forego participation in any clinical trial with an investigational drug or device during the observational study

Exclusion Criteria

The investigator has the right to exclude any individual from participating in the study if s/he deems it in the best interest of the participant or if the participant’s enrollment could impact data validity

Study & Design

• Study Type: Observational
• Study Design: Not specified